Roche has bolstered its early-stage pipeline by entering a collaboration with small US biotech company Inovio Pharmaceuticals. Roche is paying $10m upfront for exclusive worldwide rights to two of Inovio's preclinical immunotherapies targeting prostate cancer and hepatitis B.
Roche has bolstered its early-stage pipeline by entering a collaboration with small US biotech company Inovio Pharmaceuticals. Roche is paying $10m upfront for exclusive worldwide rights to two of Inovio's preclinical immunotherapies targeting prostate cancer and hepatitis B.
Roche's license covers Inovio's DNA-based vaccines INO-5150 (targeting prostate cancer) and INO-1800 (targeting hepatitis B) as well as the use of Inovio's Cellectra electroporation technology for delivery of the vaccines
Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.
Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.
The collaboration, supported by UK and Singapore government agencies, aims to develop an mRNA-based, needle-free universal bird flu vaccine suitable for use in a pandemic.
The US FDA approved Blujepa for the treatment of uncomplicated urinary tract infections, marking the first new mechanism of action for the infection in more than 30 years.
The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.
Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.
Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.
